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Abstract
Background: Depression and alcohol use disorder have been shown to be associated with poor adherence
to antiretroviral therapy (ART). Studies examining their association with viral suppression in rural Africa are,
however, scarce.
Methods: This study reports prevalence of depressive symptoms and alcohol use disorder, and their potential
association with adherence and viral suppression in adult patients on ART in ten clinics in rural Lesotho,
Southern Africa.
Results: Among 1,388 adult patients (69 % women), 80.7 % were alcohol abstinent, 6.3 % were hazardous
drinkers (men: 10.7 %, women: 4.4 %, p < 0.001). The prevalence of depressive symptoms was 28.8 % (men
20.2 %, women 32.7 %, p < 0.001). Both alcohol consumption (adjusted odds-ratio: 2.09, 95 % CI: 1.58-2.77)
and alcohol use disorder (2.73, 95 % CI: 1.68-4.42) were significantly associated with poor adherence. There
was, however, no significant association with viral suppression.
Conclusions: Whereas the results of this study confirm previously reported association of alcohol use
disorder with adherence to ART, there was no association with viral suppression.
Trial registration: April 28th 2014; NCT02126696.
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Background
Despite enormous progress in the roll out of HIV preven-
tion and treatment, 2 million new HIV infections and 1.2
million AIDS-related deaths were reported globally in
2014 with Sub-Saharan Africa bearing the highest burden
of morbidity and mortality [1].
For many individuals infected with HIV, the scale-up of
antiretroviral therapy (ART) has, however, transformed
HIV into a chronic disease that does affect their lives, but
does not necessarily shorten their life expectancy, as long
as continued adherence is maintained [2, 3]. As HIV has
turned into a chronic but manageable condition new
challenges arise for the patients and health care providers.
Good adherence to ART is particularly decisive for
biological and clinical outcomes [4, 5]. Evidence-based
recommendations for improving adherence include,
among many others, targeting patients with substance
abuse and mental illness [6]. Several studies report depres-
sion as well as alcohol use disorder to be associated with
poor adherence to ART in Africa [7–9]. However, most
studies look at self-reported or observed adherence, both
prone to reporting-bias. Viral suppression is an observer-
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independent reflection of drug-adherence and viral load
monitoring may be used as an adherence-monitoring tool
[10]. Data examining association of depression and alco-
hol use disorder with viral suppression in Southern Africa
are, however, very limited.
Lesotho, an impoverished, landlocked country sur-
rounded by South Africa has the third-highest HIV
prevalence in the world [11] and has the highest
transmission-rates and the lowest ART-coverage [12]
among the hyper-endemic countries in Southern Africa.
In this paper we report on prevalence of depressive
symptoms and alcohol use, and their potential associ-
ation with viral suppression in adult patients on ART in
rural Lesotho, Southern Africa.
Methods
Study setting and participants
The study Comorbidities and Virologic Outcome Among
Patients on Anti-retroviral Therapy in Rural Lesotho
(CART-1) is a registered observational study assessing
comorbidities and virologic outcomes among patients on
first-line ART in Lesotho (registration: April 28th 2014;
NCT02126696). Lesotho is a small landlocked country
surrounded by South Africa. It has an adult HIV-
prevalence of 23.4 % [13] and on-going high transmis-
sion rates [12]. Due to severe shortage of medical
personnel, HIV/AIDS care is nurse-based in most
clinics. The CART-1 study was conducted in two rural
districts, Butha-Buthe and Thaba-Tseka. In each district
one hospital and four nurse-led health centres were in-
cluded. All involved facilities receive support through
SolidarMed, a Swiss non-for-profit organization that has
been assisting the Ministry of Health in the roll out of
ART since 2005. During the CART-1 study, all patients
on ART ≥ 6 months attending routine follow-up visits
between May 5th, 2014 and June 17th, 2014 and willing to
participate received viral load measurement and extensive
comorbidity screening, including assessment for alcohol
use disorder and depressive symptoms. The study-setting
has been described elsewhere [14, 15]. Exclusion criteria
were being on ART < 6 months, history of treatment
interruption ≥ 7 days during the last 3 months, receiving
second-line ART.
For the present analysis, patients aged ≥ 16 years with
documented viral load, alcohol use disorder and depressive
symptoms screening were included.
Measures
Participants were enrolled and screened at their rou-
tine ART-visits during the study-period. A trained lay-
counsellor collected basic socio-demographic data, assessed
adherence and subsequently conducted screening for alco-
hol use disorder and depressive symptoms. The latter were
screened for using the Alcohol use Disorder Identification
Test (AUDIT) [16] and the nine-item depression mod-
ule from the Patient Health Questionnaire (PHQ-9)
[17] respectively. Both screening tools have been used
in similar settings [7–9]. Interviews were conducted in
a separate closed room to ensure confidentiality. The
internationally recommended thresholds for “hazardous
drinker” (AUDIT-score ≥ 8) “alcohol dependence” (AUDIT-
score ≥ 20) and depression (PHQ-9 score ≥ 10) were used,
as in other studies in Sub-Saharan Africa [18–21]. AUDIT
and PHQ-9 questionnaires were translated by a profes-
sional English-Sesotho translator and translated back into
English by study-personnel. Meaning of questions after
back-translation into English was unchanged. Thereafter,
the Sesotho questionnaires were discussed in focus groups
involving community workers, health care providers and
patients where group members agreed on some minor
grammar modification.
After the interviews patients attended their routine ART-
consultation and blood for biologic analyses was taken.
Routine laboratory exams (full blood count, CD4-cell
count, serum gamma-glutamyl transferase, and serum cre-
atinine) were performed at the laboratories of the two
hospitals involved in the study, which are both certified
national laboratories. Blood for the viral load analyses was
collected in a Plasma Preparation Tube (PPT), centrifuged
within eight hours and subsequently frozen at - 40 °C. PPTs
were shipped on dry ice within a maximum of 3 weeks to a
reference laboratory in Switzerland. Viral RNA was pre-
pared using an automated extractor (NucliSENS easyMAG,
Biomerieux, Switzerland) and quantified using a validated
protocol as published [22]. Based on established sensitivity
of the protocol, viral suppression was defined as a viral
load <80 copies/mL. Adherence was assessed through
two different approaches: self-reported adherence using
a visual analogue scale (VAS), and pill-count. Low ad-
herence criteria were defined as a VAS-score ≤95 %, or a
pill-count <95 %. VAS ≤ 95 % was associated to virologic
failure in a previous study in the same setting [23]. Pill-
count ≤95 % has been shown to be associated to lower rates
of viral suppression in similar settings [24] Participants’
wealth index was assessed using the 2009 Lesotho Demo-
graphic Health Survey questionnaire [25], which includes
the following variables: type of floor, roof, and walls of the
house; type of beds, toilet; material used for cooking; access
to water; electricity supply; equipment of the household
(electricity generator, radio, tv, fix and mobile phone, watch,
fridge, bed, computer, access to Internet, bicycle, cart,
motorbike, car); owned surface of land; and a complete
description of the owned cattle and sheep.
Analysis
Unless specified, mean results and odd ratios (OR) are
given with 95 % confidence intervals. Link between dichot-
omous variables and other covariates were investigated with
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generalized linear models with binomial function links, and
the different models were compared with chi square test
based on the analysis of deviance. For the prevalence or al-
cohol use, depressive symptoms, self-reported adherence,
and viral suppression, difference between gender were ad-
justed by age and wealth index. For virologic suppression,
the link with the following covariates were investigated: age,
sex, wealth index, type of health facility (health centre or
hospital), nucleosid reverse transcriptase inhibitor (NRTI)
and non-nucleosid-reverse transcriptase inhibitor (NNRTI)
of the current ART-regimen, PHQ score, AUDIT score,
and self-reported adherence (VAS and pill count). The
wealth-index was generated through principal component
analysis [26]. Links between two categorical variables were
investigated with Chi-squared test. All analyses were
run on R 2.15.3 (the R Foundation for Statistical Com-
puting), and TIBCO Spotfire S + ® 8.1 for Windows
(TIBCO Software Inc).
Results
A total of 1,811 adult patients attended ART-consultations
during the study-period, 213 (11.8 %) were excluded due to
pre-specified exclusion criteria (138 on ART < 6 months, 50
refused participation, 25 on second-line ART) and 35
(1.9 %) due to missing viral load data. Among the 1,563
patients, 1,388 (88.8 %) had both, documented PHQ-9
and AUDIT scores. Main results, stratified by sex, are
summarized in Table 1.
Alcohol use
The proportion of alcohol abstainers (past 12 months)
was 80.7 % (78.6 %-82.8 %; men 68.8 %, 64.4 %-73.2 %;
woman 86.0 %, 82.8-88.2 %; p < 0.001), and rose from
73.8 % for the lowest quintile of the wealth index to
86.6 % for the highest one (p = 0.002). There were 6.3 %
of hazardous drinkers (5.1 %-7.6 %; men 10.7 %, 7.7 %-
13.6 %; women 4.4 %, 3.1 %-5.7 %, p < 0.001), and 0.3 %
of dependent drinkers. Among those who drink, the
average AUDIT score was 5.92 (5.27-6.56; men 6.16,
5.33-7.00; women 5.67, 4.68-6.66; p = 0.454). The level of
gamma-glutamyl transferase correlated significantly with
the AUDIT score (correlation of the log values: 0.223;
p < 0.001).
Depressive symptoms
The average PHQ-9 score was 6.61 (6.31-6.91; men 5.53,
5.01-6.06; women 7.09, 6.73-7.46; p < 0.001), and the
prevalence of depression (PHQ-9 score ≥10) was 28.8 %
(26.4 %-31.2 %; men 20.2 %, 16.4 %-24.0 %; women
32.7 %, 29.7 %-35.6 %; p < 0.001). Depression prevalence
Table 1 Distribution of age, AUDIT and PHQ scores, treatment adherence, and viral suppression
Overall n = 1,388 Women n = 958 Men n = 430 Odds-ratioa
(95 % CI)
p-value Adjusted odds-ratiob
(95 % CI)
Adjusted
p-valueb
Median age (IQR) 43.6 (34.5–53.5) 43.6 (34.5–53.5) 40.8 (32.4–51.4) <0.001 . .
Alcohol consumption Yes 268 (19.3 %) 134 (14.0 %) 134 (31.2 %) 0.35 (0.27-0.47) <0.001 0.37 (0.28-0.50) <0.001
No 1,120 (80.7 %) 824 (86.0 %) 296 (68.8 %)
Mean AUDIT Score (SD)
among drinkers
5.9 (5.4) 5.7 (5.8) 6.2 (4.9) . 0.454 . 0.491
Hazardous consumption
(AUDIT≥ 8)
Yes 88 (6.3 %) 42 (4.4 %) 46 (10.7 %) 0.38 (0.25-0.59) <0.001 0.39 (0.25-0.60) <0.001
No 1,300 (93.7 %) 916 (95.6 %) 384 (89.3 %)
Alcohol dependence
(AUDIT≥ 20)
Yes 4 (0.3 %) 3 (0.3 %) 1 (0.2 %) . . . .
No 1,384 (99.7 %) 955 (99.7 %) 429 (99.8 %)
Mean PHQ Score (SD) 6.6 (5.8) 7.1 (5.8) 5.5 (5.6) . <0.001 . <0.001
Moderate to severe
depression (PHQ-9≥ 10)
Yes 400 (28.8 %) 313 (32.7 %) 87 (20.2 %) 1.89 (1.45-2.49) <0.001 1.92 (1.45-2.54) <0.001
No 988 (71.2 %) 645 (67.3 %) 343 (79.8 %)
Mean VAS (SD) 92.0 (12.2) 91.9 (12.3) 92.2 (12.0) . 0.713 . 0.701
Low VAS (≤95 %) Yes 610 (44.7 %) 419 (44.6 %) 191 (45.0 %) 0.97 (0.77-1.23) 0.823 0.97 (0.76-1.23) 0.780
No 754 (55.3 %) 521 (55.4 %) 233 (55.0 %)
Mean pill count Score (SD) 96.9 (8.3) 97.1 (8.1) 96.6 (8.6) . 0.333 . 0.380
Low pill count (≤95 %) Yes 301 (22.6 %) 196 (21.3 %) 105 (25.5 %) 0.79 (0.60-1.04) 0.093 0.81 (0.61-1.08) 0.148
No 1,029 (77.4 %) 723 (78.7 %) 306 (74.5 %)
Viral Suppression
(≤80 copies/m)
Yes 1,270 (91.5 %) 883 (92.2 %) 387(90.0 %) 1.31 (0.88-1.94) 0.187 1.43 (0.96-2.16) 0.088
No 118 (8.5 %) 75 (7.8 %) 43 (10.0 %)
athe group of reference is the male population
badjusted by age and wealth index
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decreased from 33.7 % for the lowest quintile of the
wealth index to 20.4 % for the highest one (p = 0.002).
There was a significant but weak correlation of 0.09
(p < 0.001) between AUDIT and PHQ-9 (men: 0.15,
women: 0.10), and no evidence of association between
PHQ-9 and the NNRTI (efavirenz versus nevirapine)
of the current ART regimen (p = 0.521):
Virologic suppression
The rate of patients who did not achieve virologic
suppression was 8.5 % (7.0 %-10.0 %; see Table 2 for
further details), with no evidence of difference between
sex (p = 0.158) or wealth index quintiles (p = 0.293). Nei-
ther depression (Odds ratio (OR) 1.27; 0.82-1.96), nor
any alcohol consumption (OR 0.94; 0.58-1.51), nor haz-
ardous alcohol consumption (OR 0.81; 0.39-1.65), showed
significant association with unsuppressed viremia. In a
complementary analysis, we applied different cut-off values
for VAS and pill count suggested by Denison et al. [27]
after ROC curve analysis. We also applied different AUDIT
cut-off values for the hazardous consumption of alco-
hol as sometimes suggested (≥7 for males, respectively ≥ 6
for females). In both situations the conclusions remained
unchanged.
Adherence
The median adherence measured with the VAS was 96 %
(interquartile range (IQR): 91 %-99 %), with no evidence
Table 2 Viral suppression and association with socio-demographic characteristics, type of ART-regimen, AUDIT and PHQ scores, and
treatment adherence
Viral load <80 c/mL ≥80 c/mL Odds-ratio viral suppression (95 % CI) p-value
Male 387 (90.0 %) 43 (10.0 %) 1
Female 883 (92.2 %) 75 (7.8 %) 1.33 (0.90-2.00) 0.158
Median age (IQR) 43.6 (34.5–53.9) 41.4 (33.2–50.2) 0.181a
Age <35 years 334 (90.3 %) 36 (9.7 %) 1 0.329
≥35 years 936 (91.9 %) 82 (8.1 %) 1.23 (0.81-1.86)
Median wealth index (IQR) −0.52 (−1.66-1.25) −0.90 (−1.76-1.13) 0.180a
Wealth index Q1b 253 (90.7 %) 26 (9.3 %) 1 0.293
Q2 249 (88.9 %) 31 (11.1 %) 0.83 (0.41-1.64)
Q3 250 (92.6 %) 20 (7.4 %) 1.28 (0.60-2.75)
Q4 258 (93.8 %) 17 (6.2 %) 1.56 (0.70-3.46)
Q5 260 (91.5 %) 24 (8.5 %) 1.11 (0.54-2.31)
Type of facility Center 768 (91.9 %) 68 (8.1 %) 1 0.547
Hospital 502 (90.9 %) 50 (9.1 %) 0.89 (0.61-1.30)
NRTI backbone AZTc/3TCd 418 (87.8 %) 58 (12.2 %) 0.52 (0.34-0.80) 0.004
TDFe/3TCd 819 (93.3 %) 59 (6.7 %) 1
ABCf/3TCd 13 (92.9 %) 1 (7.1 %) 0.94 (0.09-9.80)
NNRTI EFVg 959 (92.2 %) 81 (7.8 %) 1 0.056
NVPh 291 (88.7 %) 37 (11.3 %) 0.66 (0.44-1.00)
Median AUDIT Score (IQR) 0 (0–0) 0 (0–1.0) 0.384a
Hazardous consumption Yes 79 (89.8 %) 9 (10.2 %) 0.80 (0.39-1.65) 0.559
(AUDIT≥ 8) No 1’191(91.6 %) 109(8.4 %) 1
Median PHQ-9 Score (IQR) 6 (1–10) 6 (1–9) 0.423a
Moderate to severe depression (PHQ-9≥ 10) Yes 371 (92.8 %) 29 (7.3 %) 1.27 (0.82-1.96) 0.281
No 899 (91.0 %) 89 (9.0 %) 1
VAS (IQR) 96 (91–99) 96 (90–100) 0.424a
Low adherence VAS (≤95 %) Yes 558 (91.5 %) 52 (8.5 %) 1.02 (0.70-1.50) 0.818
No 691 (91.6 %) 63 (8.4 %) 1
Pill count’s tool (IQR) 100 (96–100) 100 (96–100) 0.851a
Low pill count’s tool (≤95 %) Yes 275 (91.4 %) 26 (8.6 %) 0.99 (0.63-1.56) 0.999
No 941 (91.4 %) 88 (8.6 %) 1
a: Wilcoxon rank-sum test, b: lowest quintile, cAZT: zidovudine, d3TC: lamivudine, eTDF: tenofovir, fABC: abacavir, g: efavirenz, h: nevirapine
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of difference between sex (p = 0.713). The prevalence of
VAS ≤ 95 % was 44.7 % (p = 0.823 for difference between
sex), decreased from 22.6 % for the lowest quintile of the
wealth index to 16.2 % for the highest one (p < 0.001), and
did not show evidence of association with depressive
symptoms (p = 0.386). Hazardous alcohol consumption in-
creased the probability of VAS ≤ 95 % (OR 2.89; 1.79-4.66;
adjusted by wealth index, type of facility, depressive symp-
toms: 2.73, 1.68-4.42). For alcohol consumption, these re-
sults were 2.19 (1.67-2.90) and 2.09 (1.58-2.77) respectively.
The median adherence measured by pill count was 100 %
(IQR 96 %-100 %), with some evidence of lower adherence
among men (99 % vs. 100 %; p = 0.036). The prevalence of
pill count ≤ 95 % was 22.6 % (p = 0.093 for difference be-
tween sex), and did not show evidence of association with
depressive symptoms (p = 0.725), Hazardous alcohol con-
sumption increased the probability of low pill count (1.77,
1.08-2.89; adjusted by type of facility and age: 1.68; 1.03-
2.75). For alcohol consumption, these results were respect-
ively 1.48 (1.09-2.02) and 1.38 (1.01-1.89).
Discussion
Main findings
This cross-sectional study is among the first reporting
on prevalence of depressive symptoms and hazardous
alcohol use among adult patients on ART investigating
their association with unsuppressed viremia in rural
Southern Africa. In line with other studies conducted in
similar settings, we found hazardous alcohol use to be
associated with low self-reported (VAS) adherence to
ART [28, 29] or pill count. In addition we also found
and association between adherence and alcohol consump-
tion. However, neither hazardous alcohol consumption
nor depressive symptoms appeared to be associated with
viral suppression through ART.
As an observational cross-sectional facility-based study,
interpretation of the results should be limited to patients
retained on ART ≥ 6 months. Our study population
mainly involved women (69.0 %). This is however repre-
sentative for the gender-distribution in patients enrolled
on ART in Lesotho [15].
Alcohol consumption
Overall alcohol-consumption and rate of hazardous al-
cohol use were lower than in a recently conducted
survey in the general population [28, 29], and are nega-
tively correlated with the wealth index. The significant
association between the level of gamma-glutamyl trans-
ferase and the AUDIT confirmed the validity of the
instrument in this setting. The proportion of alcohol
abstainers in our study-population (68.8 % for men, and
86.0 % for women respectively), was similar [30] or
higher [31] to the one observed in other studies. Alcohol
abstinence was significantly higher than in the general
adult population of Lesotho [32] (58.0 % for men and
81.3 % for women). One explanation may be that in
general ART-providers at facilities involved advocate for
alcohol abstinence when a patient decides starting ART.
The amplitude of the effect of hazardous alcohol con-
sumption on low adherence (adjusted OR 2.72) is higher
to the one found in the literature: a meta-analysis pub-
lished by Hendershot and colleagues in 2009 reported an
OR of 1.82 [33]; Denison et al. report a pooled OR of 1.87
[27], and Ayay et al. 2.17 [30]. However, these studies did
not examine for association with viral suppression.
Depressive symptoms
In contrast to alcohol consumption, depressive symptoms
(31.7 % of women and 20.2 % of men) showed a consider-
ably higher prevalence than the reported 10 % in the
general population [34]. There was also a negative associ-
ation of depressive symptoms with the wealth index. This
outcome is similar to the one of the systematic review
done by Nakimuli-Mpungu et al. in 2012 [35], with a
prevalence of 31.2 %. Our study showed no association of
depressive symptoms with viral suppression. This finding
is in contrast to the study of Marconi et al. reporting
association of depression to unsuppressed viremia in a
case–control study [36]. The stronger association between
AUDIT- and PHQ-9-score among men in our study
suggests that particularly among men alcohol consump-
tion should be addressed in cases where of symptoms of
depression are found.
Limitations
This study has several limitations: first, it was carried
out in two rural districts of Lesotho, and may not be
representative of the situation in the whole country – in
particular as it does not involve urban areas. Also, whereas
the design of CART-1 could reduce bias when compared to
a case control study, the hypothesis of biases cannot be
ruled out: many variables collected through questionnaires
require recall of past events by the participant. Another
limitation is the potential of distortion affecting the asso-
ciation between viral suppression and self-reported ad-
herence due the negative cognitive bias in people with
depressive symptoms. Moreover, the study involved only
patients on ART ≥ 6 months attending routine follow-up
visits: prevalence of alcohol use, depressive symptoms,
reported adherence is likely to be different among those
patients who have been lost to follow-up. Also PHQ-9 and
AUDIT were used at the time of enrolment, which did not
allow the study of their evolution in time. Finally we were
not able to perform multivariate analysis to adjust for
confounding when investigating unsupressed viral load due
to the small number of patients with viral load <80 c/mL.
Internationally recommended cut-offs for PHQ-9 and
AUDIT were used in this study. PHQ-9 has been used
Cerutti et al. BMC Public Health  (2016) 16:947 Page 5 of 7
to screen HIV-infected persons for depression in several
settings in Sub-Sahara Africa [9, 37–40]. Two independent
studies, one from Ethiopia and one from Uganda con-
cluded that a score ≥10 was most accurate to diagnose
moderate to severe depression [19, 20]. Nevertheless,
PHQ-9 and the used cut-off of 10 for diagnosis of depres-
sion has never been validated in Lesotho specifically. Simi-
larly, AUDIT and the cut-offs applied in our study were
never used in Lesotho. There are, however, several studies
validating AUDIT and the cut-off of ≥8 and ≥20 for “haz-
ardous alcohol use” and “dependence” in similar settings
of neighbouring South Africa [21, 41, 42].
Conclusions
A worth reporting finding in our study is that contrarily to
many other publications neither self-reported adher-
ence nor pill-count were associated to viral suppres-
sion. Whereas in study settings with well-trained
health care providers pill-count and self-reported adherence
showed to be predictive for virolologic outcomes, they ap-
pear to be imprecise in the setting our study was conducted
[24, 43]. Similarly Haberer et al. report from a study
in Uganda where pill-count and self-reported adher-
ence showed poor correlation to virologic outcomes [44].
With the expected roll-out of viral load technologies in
resource-limited settings, routine viral load monitoring –
a more objective adherence measurement - may replace
traditional adherence measurement in future [10].
In summary, prevalence of depressive symptoms was
generally high and increased inversely to household wealth
in this population of ART-patients on rural Lesotho, but
no association to virologic outcomes could be shown.
Prevalence of hazardous alcohol use was lower than in the
general population and increased inversely to household
wealth. Prevalence among females was very different than
among males, underlining the importance of gender-
disaggregated data. Hazardous drinking was associated to
poor adherence, but not to unsuppressed viral load.
This study underlines the need for integration of men-
tal health care into ART-services. Health care providers
should be encouraged to address with their patients
alcohol use and depressive symptoms.
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